Research Guide
A clear GLOW and KLOW peptide guide covering ingredients, benefits, milligram ratios, dosage math, reconstitution and cited safety evidence.
If you are comparing GLOW peptide and KLOW peptide, start with composition. They are blend formats, not single compounds, and everything about their dosing follows from the ratio printed on the vial — which varies by supplier.
Educational and research information only. Nothing here is medical advice, prescribing guidance or a recommendation to use any compound. Consult a licensed healthcare professional before any health decision.
GHK-Cu supports collagen production, skin health and tissue remodelling. BPC-157 is studied in muscle, tendon, ligament and gut-lining repair. TB-500 is a synthetic thymosin beta-4 fragment linked to new blood-vessel formation and cell repair. KPV is an anti-inflammatory tripeptide associated with immune regulation and barrier health.
In a blend you cannot move one component without moving the others. Dose is a volume decision, so research planning normally proceeds in three steps:
Take an 80 mg KLOW vial reconstituted with 4 mL of bacteriostatic water — 20 mg/mL total:
A GLOW vial without KPV uses the same method with its own total. Add water slowly down the vial wall, swirl rather than shake, and refrigerate after mixing.
Reference cycles mirror the repair peptides inside them: 4 to 6 week blocks, then a break to reassess. Because the combination has never been trialled as a combination, effects attributed to a blend cannot be separated between its components.
Angiogenic activity across several components leaves tumour-biology questions unresolved, a clear reason for caution with any current or prior cancer diagnosis. Copper load rises with volume, injection-site irritation is commonly reported with GHK-Cu, and none of these components is an FDA-approved drug. BPC-157 and TB-500 are both on the WADA prohibited list.
Published research reference
Trial / research dose bands
Reported side effects
Cited studies
Educational research reference only — not medical advice.
Published research reference
Trial / research dose bands
Reported side effects
Cited studies
Educational research reference only — not medical advice.
What is GLOW peptide?
GLOW is a three-part peptide blend of GHK-Cu, BPC-157 and TB-500 in a single vial. A common configuration is 50 mg GHK-Cu with 10 mg each of BPC-157 and TB-500, though ratios vary by supplier and the label should always be read before any math is done.
What is KLOW peptide?
KLOW is GLOW plus KPV. A standard 80 mg KLOW vial usually follows a 50/10/10/10 milligram ratio: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg and KPV 10 mg.
What does each component contribute?
GHK-Cu is a copper peptide associated with collagen production, skin health and tissue remodelling. BPC-157 is studied in muscle, tendon, ligament and gut-lining repair models. TB-500 is a thymosin beta-4 fragment linked to new blood-vessel formation and cell migration. KPV is an anti-inflammatory tripeptide associated with immune regulation and barrier health.
How are blend doses worked out?
Because the components are fixed in one vial, dose is set by the total volume drawn, and every component scales together. Research planning generally anchors on the BPC-157 and TB-500 content, then checks that the GHK-Cu amount that comes with it stays inside its own reference band.
How is a blend vial reconstituted?
The same way as a single peptide: bacteriostatic water added slowly down the vial wall, swirled rather than shaken. For an 80 mg KLOW vial with 4 mL of water, total concentration is 20 mg/mL, so 0.1 mL (10 units) delivers about 1.25 mg GHK-Cu and 0.25 mg each of BPC-157, TB-500 and KPV.
Are blends studied as blends?
No. Each component has its own preclinical literature; the combinations do not have dedicated human trial data. A blend is a convenience format, not an evidence category.
What are the main safety concerns?
The angiogenic activity shared by several components raises unresolved tumour-biology questions, which is a clear reason for caution with any current or prior cancer diagnosis. Copper load matters with GHK-Cu at higher volumes, injection-site reactions are commonly reported, and a fixed ratio removes the ability to adjust one component independently.
Track it properly
Members get illustrated infographics for every blend, log doses and cycles in one place and read the full Peptide Academy breakdown for each component.